This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Pretargeting: A Path Forward for Radioimmunotherapy
- Quantitative Immuno-SPECT Monitoring of Pretargeted Radioimmunotherapy with a Bispecific Antibody in an Intraperitoneal Nude Mouse Model of Human Colon Cancer
- Introduction to monoclonal antibodies
- Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
- Pretargeted 177Lu Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colonic Tumors in Mice
- Pretargeted Immuno-Positron Emission Tomography Imaging of Carcinoembryonic Antigen-Expressing Tumors with a Bispecific Antibody and a 68Ga- and 18F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts
- Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody
- Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting
- A Divalent Hapten-Peptide Induces Apoptosis in Human Non-Hodgkin Lymphoma Cell Lines Targeted by Anti-CD20 x Anti-Hapten Bispecific Antibodies
- Bispecific Antibody Pretargeting of Radionuclides for Immuno-Single-Photon Emission Computed Tomography and Immuno-Positron Emission Tomography Molecular Imaging: An Update
- Evaluation of CD20, CD22, and HLA-DR Targeting for Radioimmunotherapy of B-Cell Lymphomas
- Bispecific Antibody Pretargeting PET (ImmunoPET) with an 124I-Labeled Hapten-Peptide
- Bispecific Antibody Pretargeting of Tumor Neovasculature for Improved Systemic Radiotherapy of Solid Tumors
- Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas
- Imaging Experimental Atherosclerotic Lesions in ApoE Knockout Mice: Enhanced Targeting with Z2D3-Anti-DTPA Bispecific Antibody and 99mTc-Labeled Negatively Charged Polymers
- Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
- Targeting, Toxicity, and Efficacy of 2-Step, Pretargeted Radioimmunotherapy Using a Chimeric Bispecific Antibody and 131I-Labeled Bivalent Hapten in a Phase I Optimization Clinical Trial
- Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft
- Pretargeting of Carcinoembryonic Antigen-Expressing Cancers with a Trivalent Bispecific Fusion Protein Produced in Myeloma Cells
- Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods
- The Direct Route May Not Be the Best Way to Home
- Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies
- Reagents and Methods for PET Using Bispecific Antibody Pretargeting and 68Ga-Radiolabeled Bivalent Hapten-Peptide-Chelate Conjugates
- Development of New Multivalent-bispecific Agents for Pretargeting Tumor Localization and Therapy
- Pharmacokinetics and Dosimetry Studies for Optimization of Anti-Carcinoembryonic Antigen x Anti-Hapten Bispecific Antibody-mediated Pretargeting of Iodine-131-labeled Hapten in a Phase I Radioimmunotherapy Trial
- Optimizing Bispecific Antibody Pretargeting for Use in Radioimmunotherapy
- Pretargeted Radioimmunotherapy of Cancer: Progress Step by Step
- A Universal Pretargeting System for Cancer Detection and Therapy Using Bispecific Antibody
- Molecular Advances in Pretargeting Radioimunotherapy with Bispecific Antibodies
- A 3-Step Pretargeting Strategy to Image Infection
- Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity
- Pretargeting of Renal Cell Carcinoma: Improved Tumor Targeting with a Bivalent Chelate